EVP – Operations Transformation — Diagnostic-Services Platform

The mandate

A diagnostic-services platform requires an urgent replacement EVP – Operations Transformation to create controlled flow from collection to clinical receipt. Experienced teams currently prevent adverse outcomes through individual intervention, but sustainable operation depends on embedded process rather than people recognising every exception in time.

Approximately 600 employees and material partners operate collection points, courier routes, laboratories, imaging services, reporting centres, customer support and technical functions. The EVP owns operations, transformation delivery, network flow, service performance, operational technology adoption and frontline capability, reporting to the Group Chief Executive or nominated sponsor. Laboratory directors and authorised clinicians retain independent release and professional judgement.

The recovery begins with direct observation. The EVP will follow real specimens and reports across normal, peak and after-hours conditions, including manual entry, rejected samples, analyser downtime and amended findings. Procedure documents will be compared with actual work. Where teams maintain unofficial logs or messaging groups, the underlying control need must be understood before the workaround is removed.

Specimen identity requires positive control at each custody change. Labels, orders, containers, aliquots and electronic records must reconcile before processing continues. The EVP will define stop conditions and escalation so staff do not resolve ambiguity by assumption. Repeat collection will be measured by cause and patient consequence, not hidden inside general rejection totals.

Transport must be designed around stability, priority and contingency. Courier schedules that look efficient on average can expose temperature-sensitive or urgent specimens. The EVP will set route-level controls, packaging standards, chain-of-custody evidence and alternative arrangements when traffic, weather or equipment disruption occurs. Handover time and condition should be visible at laboratory intake.

Inside laboratories, turnaround improvement cannot mean pushing queues blindly. Work will be segmented by clinical urgency, specimen stability, analyser family and specialist review. The leader will address bottlenecks through layout, batching, maintenance, staffing and decision rules. Any change in workflow needs quality validation before scale, with parallel processes retired deliberately.

Critical-result communication is an end-to-end operation. The EVP will establish recipient validation, acknowledgement, escalation and unresolved-case ownership across routine and after-hours pathways. Call-centre completion is not enough if the responsible practitioner has not accepted the result. Exception ageing should trigger senior intervention before a service-level breach becomes a safety event.

Amended reports require disciplined learning. The platform will distinguish correction of demographic, transcription, interpretive and analytical issues, then examine recurrence and downstream communication. The EVP must ensure the original and amendment are traceable and that every affected recipient is informed. Productivity targets will not discourage appropriate amendment.

Equipment reliability is intertwined with flow. Maintenance deferrals, reagent availability and interface instability create hidden queue risk. The transformation portfolio will rank assets by clinical consequence and recovery time, define spare and failover strategies and test transfer to alternative platforms. Nominal capacity on an unvalidated backup is not resilience.

Workforce capability will be assessed by station and scenario. Staffing numbers can conceal dependence on a small group able to troubleshoot interfaces, unusual samples or specialist processes. The EVP will introduce cross-training and observed sign-off, protect supervision for new staff and create succession for critical operational knowledge. Agency or overtime reduction will follow process stability rather than precede it.

Daily management will use a limited set of trustworthy measures: specimens awaiting accession, stability exposure, analyser constraint, exception age, critical acknowledgement and backlog by clinical priority. Teams need authority to respond. A central dashboard that reports yesterday's failure without changing today's work is not operational control.

Transformation methods must respect diagnostic validation. Automation, middleware rules and scheduling changes will move through risk assessment, user testing, clinical acceptance and controlled release. Benefits will be measured against quality and total flow. The EVP will resist deploying technology to create an appearance of progress before the exception pathway is safe.

What you will own

• End-to-end specimen and report operations.
• Quality-recovery execution with independent clinical partners.
• Collection, transport, laboratory and reporting flow.
• Critical-result and amended-report operating controls.
• Equipment continuity and validated failover.
• Frontline capability, cross-training and succession.
• Daily management, operational data and escalation.
• Transformation sequencing and benefits delivery.

The first 12 months

In the first 30 days, trace representative high-risk journeys, place safeguards around uncontrolled hand-offs and publish a recovery baseline. Identify where current service data understate exception ageing or patient consequence.

By month five, implement custody and critical-result standards, stabilise priority queues and validate equipment contingencies. Establish observed competency for roles carrying the largest operational risk.

At twelve months, reduce pre-analytical recollection by 40%, cut overdue critical-result acknowledgement by 75% and improve the 90th-percentile turnaround for priority services by 30%. At least 98% of custody transitions should have complete evidence, with zero uncommunicated amended report from a known process failure and 90% of critical stations covered by two independently signed-off people.

What the sponsor will test

• Normal work matching controlled procedure.
• Identity and custody uncertainty producing an immediate stop.
• Urgent flow protected without distorting routine queues.
• Result acknowledgement verified to the responsible recipient.
• Failover proved under realistic operating conditions.
• Transformation benefits surviving peaks and staff absence.

The person

You bring 22–28 years in diagnostics, laboratories, imaging, healthcare operations or another clinically regulated flow environment, including enterprise transformation responsibility. You have personally recovered a service where quality events arose from hand-offs and exception handling rather than a single technical defect.

Candidates should show command of laboratory or diagnostic operations, equipment continuity, workforce competency and digital workflow release. Singapore operating experience is important, with wider regional network exposure valued. The appointment is onsite because recovery leadership must remain visible within collection and processing operations.

Compensation and terms

Base compensation is SGD 420,000–570,000 plus annual incentive and long-term participation tied to quality recovery, turnaround, control adherence, continuity and workforce capability. This is a permanent onsite role in Singapore, accountable to the Group Chief Executive or nominated executive-committee sponsor. Replacement is urgent, while a controlled handover will protect current recovery actions.

Confidentiality

The platform, laboratories, collection network, patients, specimens, reports, equipment, systems and recovery findings are confidential. Detail follows suitability, conflicts and signed confidentiality. Applicants must not contact diagnostic organisations, suppliers or clinicians to infer the client.